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URINARY & KIDNEY DISORDERS
PUR1
HEALTH STATUS OF ELDERLY
DIALYSIS PATIENTS
Boening AJ1, Chapman MM1, Brown RH2, Zager PG2, Meyer KB1
1New England Medical Center, Boston, MA, USA; 2Dialysis 
Clinics, Inc, Albuquerque, NM, USA
OBJECTIVES: The elderly comprise approximately half
of new patients undergoing dialysis, an expensive, lifesav-
ing treatment. We report the health status of 3 elderly age
groups, including novel information about patients 
85
years, hypothesizing that as age increases health status
will decrease. METHODS: This retrospective analysis re-
ports on 6154 patients treated by one dialysis chain
(48.4% male, 61.5% white, 39.1% diabetes as primary
diagnosis). Health status is reported by a single adminis-
tration of the SF-36 between 10/30/90 and 10/30/00. RE-
SULTS: Although not statistically significant at p  .01,
with increasing age, there are trends to lower Physical
Function and Role Physical scores. The Physical Compo-
nent Score shows a statistically significant difference be-
tween groups 1 and 2. Group 3, the very elderly, are not
significantly different from groups 1 or 2. Other scales
show no change. CONCLUSIONS: As hypothesized,
physical health of dialysis patients appears vulnerable to
age. However, other domains of health status remain ro-
bust. The very elderly receiving dialysis maintain their
mental health when compared to patients in the 2 younger
age groups. (See table below.)
PUR2
EVIDENCE OF DISEASE PROGRESSION IN 
ADULT PATIENTS WITH AN OVERACTIVE 
BLADDER (OAB)
Zhou Z1, Barr CE1, Torigoe Y1, Williamson TE1, Shah J2
1Pharmacia, Peapack, NJ, USA; 2Institute of Urology, London, UK
OBJECTIVES. This study examined patterns of transi-
tion of bladder symptoms in adult patients with an over-
active bladder, identified risk factors for such transitions,
and assessed the impact of symptom transition on patient
outcomes of depression and accidental falls. METHODS:
This study was a retrospective, population based cohort
study using the General Practice Research Database
(GPRD) containing medical records from 550 of 686
general practices in the UK. The baseline period included
the year in which a patient’s first OAB symptom or diag-
nosis record occurred and the following year. The follow-
up period was six years. A total of 9,706 patients, aged
40 years or older met the criteria. Transition rates from
frequency/urgency to incontinence, and from urge incon-
tinence to frequency/urgency were calculated. Logistic re-
gression was used to examine the impact of risk factors
on symptom transition, and its effect on a patient’s risk
of depression and accidental fall. RESULTS: Of female
patients with OAB, 23.4% had “frequency/urgency” at
baseline and developed “incontinence” in the follow-up
period—potentially reflecting progression of the condi-
tion. Factors associated with progression of OAB in-
cluded older patients (70 to 90 years), female gender, ur-
gency, accidental falls, multiple sclerosis, and epilepsy.
Controlling for these factors, patients with progression
showed an increased risk of depression and accidental
fall compared to patients who had no change in symp-
toms (adjusted odds ratios 1.44 and 1.35, respectively;
p  0.0001 for both). CONCLUSION: OAB appears to
be a progressive disease. A significant proportion of pa-
tients progressed from “dry” to “wet” symptoms. This
may imply that some patients with OAB, if left un-
treated, will develop progression of OAB over time. The
risks of depression and accidental falls were significantly
increased in those patients whose OAB condition wors-
ened. Further research is required to determine whether
treatment can prevent, reduce, or delay the progression
of OAB syndrome.
PUR3
PERSISTENCE OF THERAPY WITH DRUGS FOR 
OVERACTIVE BLADDER
Zhou Z, Barr CE, Torigoe Y, Williamson TE
Pharmacia, Peapack, NJ, USA
OBJECTIVE: This study evaluates the real world persis-
tency of therapy for overactive bladder (OAB), compar-
ing tolterodine, oxybutynin and flavoxate head-to-head
in a large sample extracted from a US drug claim data-
base. Clinical trials have shown tolterodine has equal ef-
ficacy to oxybutynin in reduction of OAB symptoms and
Table for PUR1 Mean SF-36 SCORE (SD)
1652 1
Physical
Function
Role
Physical Bodily Pain
General
Health Vitality
Social
Function
Role
Emotional
Mental
Health
Physical
Component
Score*
Mental
Component
Score
Group 1
65–74
36.9 (27.8)
n  3687
29.3 (37.9)
n  3609
58.5 (29.0)
n  3674
43.2 (20.1)
n  3587
42.7 (22.8)
n  3635
62.8 (28.8)
n  3687
55.7 (43.6)
n  3577
69.2 (20.0)
n  3621
31.8 (10.1)
n  3445
48.3 (11.3)
n  3445
Group 2
75–84
32.4 (26.2)
n  2117
26.8 (36.4)
n  2059
58.1 (28.4)
n  2111
44.2 (20.0)
n  2073
40.8 (22.4)
n  2098
61.3 (30.0)
n  2119
54.2 (43.9)
n  2038
69.5 (20.1)
n  2089
30.9 (9.4)
n  1957
48.4 (11.6)
n  1957
Group 3

85
30.0 (27.1)
n  267
26.8 (37.5)
n  257
58.7 (58.7)
n  266
46.8 (21.1)
n  254
42.1 (23.0)
n  261
63.5 (30.1)
n  267
53.6 (44.5)
n  257
71.5 (19.1)
n  258
30.7 (10.0)
n  244
49.5 (11.0)
n  244
*  p  .01
